- Home
- OPP vs SGMT Comparison
OPP vs SGMT Comparison
Compare OPP & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OPP | SGMT |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.2M | 169.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPP | SGMT |
|---|---|---|
| Price | $7.60 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 75.9K | ★ 974.6K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.47 | $4.50 |
| 52 Week High | $8.77 | $10.06 |
Technical Indicators
Market Signals| Indicator | OPP | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 48.12 |
| Support Level | $7.50 | $7.04 |
| Resistance Level | $8.03 | $7.39 |
| Average True Range (ATR) | 0.08 | 0.44 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 14.29 | 24.19 |
Price Performance
Historical ComparisonAbout OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.